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Epigenetic gene regulation has a critical role during normal
development and neoplastic transformation. Several tumor
suppressor genes are found to be abnormally methylated and
silenced in hematological malignancies, and the distribution of
DNA methylation follows specific and distinct patterns in acute
myeloid leukemia (AML) and myelodysplastic syndromes
(MDS). However, the mechanisms mediating aberrant methyl-
cytosine patterns in MDS have not been defined.
TET2 is a close relative of TET1 and TET3, a family of enzymes
sharing two highly conserved domains, which convert DNA 5-
methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC). The
gene encoding for TET2 resides at chromosome 4q24 and is
frequently mutated in myeloid malignancies, including about
25% of MDS, 40–50% chronic myelomonocytic leukemia, 15%
myeloproliferative neoplasms, 10–20% of AML, in particular in
cases secondary to MDS.1–3 Most recently, Ko et al.4 showed
that TET2 mutations compromise the hydroxymethyl-catalytic
activity of the protein, with lower levels of 5-hydroxymethylcy-
tosine in genomic DNA from TET2-mutated samples compared
with controls.
We studied the prognostic role of TET2 mutations and
methylation profiling in 38 patients treated with 5-azacytidine
(Vidaza, Celgene Corp., Summit, NJ, USA) and valproic acid,
according to the Gimema multicenter clinical trial MDS0205
(EudraCT number 2005-004811-31). Therapy consisted of
valproic acid given orally to reach a plasma concentration
above 50 mg/ml and 5-azacytidine (5-AZA) at a standard dose of
75mg/sqm daily, subcutaneously, for 7 days every 4 weeks.
Response rate and survival for the whole patient group have
been previously reported.5 The validation group was composed
of a retrospective series of 27 patients treated at the Universita’
Cattolica Sacro Cuore (Rome, Italy) between September 2007
and June 2010. Inclusion criteria were: diagnosis of higher-risk
MDS and treatment with 5-AZA at 75mg/sqm daily, subcuta-
neously, 7 days for a median of 4 cycles (range 2–30 cycles).
Clinical characteristics of these patients are described in Table 1.
Both patient groups had not received any specific treatment
before starting 5-AZA, except for supportive therapy. DNA was
extracted from bone marrow mononuclear cells obtained from
all patients before 5-AZA exposure. All patients signed informed
consent in accordance with the Declaration of Helsinki,
following institutional guidelines.
We found that TET2 was mutated in 12/38 (32%) patients with
Int-2/high risk MDS included in the Gimema multicenter study
MDS0205.5 Mutational analysis of TET2 coding exons 3–11
performed by PCR-based denaturing high pressure liquid
chromatography using a WAVE-MDTMSystem (Transgenomic,
Omaha, NE, USA) equipped with a DNASep Cartridge, detected
five frameshift, three nonsense, six missense (two recurrent and
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four putative) mutations (Figure 1a), and two putative poly-
morphisms not annotated in NCBI single-nucleotide polymorph-
isms database (c.2599T4C p.Y867H; c.5167C4T p.P1723S).3
Patient characteristics according to TET2 mutations are given in
Table 2. There were no associations with gender, IPSS score or
karyotype, but TET2 mutations were more frequent in chronic
myelomonocytic leukemia (three of four patients, 75%) versus
RAEB/RAEB-t (9 of 34 patients, 27%, P¼ 0.08). It is interesting to
note that TET2 mutations impair monocyte/macrophage differ-
entiation in culture, indicating a putative role for TET2 during
monocyte development.4 Patients with TET2 mutations tended
to have lower platelet counts at diagnosis (median platelet
counts: 27 109/l, range 11–77, versus 62 109/l, range 10–573,
P¼ 0.08), but there were no differences in the occurrence of
NCI grade 3/4 thrombocytopenia during treatment, according to
TET2 mutations.
Given the functional role of TET2 as epigenetic enzyme, we
were interested in associations between TET2 mutations,
methylation profile and response to epigenetic treatment, which
has shown efficacy in higher-risk MDS.5,6 Using Real-Time PCR
and the Custom Methyl-Profiler PCR Array (SABiosciences,
Frederick, MD, USA; Qiagen, Valencia, CA, USA), which allows
for quantification of hypermethylated versus unmethylated
promoter sequences, we studied the methylation profile of 22
differentiation, apoptosis and targets of polycomb group
proteins genes, known to be frequently mutated or methylated
in MDS or induced by hypomethylating treatment (RUNX1,
FOXO3, TET2, PTEN, DUSP1, EZH2, DAPK1, TWIST1, HOXA9,
PNPLA8, NRCAM, GLCCI1, CDH1, KLF5, OLIG1, OLIG2, BIK,
BCL6, BCL2L10, TP53, ASXL1 and SPARC) (Supplementary
Figures 1 and 2).7 Statistical analyses were performed using the
statistical software environment R (http://www.R-project.org).
Principal component analysis was performed to identify
methylation patterns. Following factor rotation, we chose four
components that could explain about 65% of variance in
methylation (screen plot as Supplementary Figure 3). Associa-
tions between the four principal components and methylation in
the 22 genes are shown in Table 3. TET2 mutations were not
associated with any of the components nor with the hyper-
methylation of any of the genes analyzed. This may be in
contrast with the reported correlation between TET2 mutations,
low genomic 5hmC content and hypomethylation at differen-
tially methylated CpG sites in patients with myeloid malig-
nancies,4 and warrants further investigations on the influence of
TET2 mutations on DNA methylation patterns.
We then studied the impact of TET2 mutations and methyla-
tion profile on outcome of higher-risk MDS patients, treated with
epigenetic therapy. Six of 38 patients were not evaluable for
treatment response due to early death or premature therapy stop.
Five of the eleven TET2-mutated patients (46%) responded to
epigenetic treatment, while only five of the 21 patients (24%) with
wild-type TET2 gene responded. Probably due to the relatively
small sample size, this difference did not reach statistical
significance (P¼ 0.2). Duration of response did not differ between
the two groups. Median overall survival was 14.4 months, with no
differences between TET2-mutated or wild-type patients (log-rank
P¼ 0.9, Figure 1b). The impact of TET2 mutations on survival is
Table 1 Characteristics of patients included in the validation group
Patients n¼27 n
Age (median, range)












Hemoglobin (g/dl) 8.9 (7.7–12.7)
Platelets (109/l, median, range) 44 (6–315)




MDS duration before 5-ZA




Abbreviations: CMML, chronic myelomonocytic leukemia; CR,
complete remission; FAB, French-American-British classification;
LR-MDS, low-risk MDS; MDS, myelodysplastic syndromes; PR, partial
remission; RAEB, refractory anemia with excess blasts.
aCMML-1:1 patient, CMML-2:3 patients.
Figure 1 Description of TET2 mutations found in 38 higher-risk MDS
patients and their impact on survival. (a) Using PCR-based denaturing
HPLC, we detected five frameshift, three nonsense and six missense
(two recurrent and four putative) TET2 mutations. (b) Overall survival
of 38 higher-risk MDS patients, treated in the Gimema MDS0205 trial
(16), according to TET2 mutational status.
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controversial. Decreased survival in TET2-mutated AML patients
has been reported by Abdel-Wahab et al.3 A study on 96 MDS
patients, including lower and higher risk MDS, mostly treated
with supportive treatment, identified mutant TET2 as a positive
prognostic marker, with 77% 5-year overall survival for TET2-
mutated patients versus 18% for wild-type patients.8 On the
other hand, TET2 mutations were not associated to IPSS score,
karyotype, World Health Organization subtypes, time to AML
transformation and overall survival in 320 MDS patients.9 The
GFM recently reported significantly higher response rates to
5-azacytidine in TET2 mutated high-risk MDS patients (n¼ 63
RAEB) and AML with low blast counts (n¼ 23 patients).10
Similar to our data, no differences for duration of response or
survival were reported.10
Promoter methylation has been shown to have a significant
role in the pathogenesis and progression of myelodysplastic
syndromes, but a reliable methylation marker, predictive of
treatment response has not been identified yet. Follo et al.11
showed that reduction of phosphoinositide-phospholipase C
beta1 methylation correlated with azacytidine response in high-
risk MDS, whereas increasing levels of promoter methylation
were observed in refractory patients. We then analyzed for
associations between methylation patterns and survival. An
association became evident between the third component,
which strongly impacts on methylation of the genes NRCAM,
BCL6, TP53 and BCL2L10, and overall survival (P¼ 0.009,
hazard ratio: 1.89, 95% confidence limits: 1.17–3.06). When
the third component was inserted into a multivariate model
including the IPSS score (Int-2 versus High), it remained a
prognostic factor for overall survival (hazard ratio: 1.63, 95%
confidence limits: 10.01–2.64, P¼ 0.047) (Supplementary
Figure 4). It is unclear how hypermethylation of the third
component influences outcome after epigenetic therapy. High
methylation levels of oncosuppressor genes might increase
resistance to epigenetic treatment. Among prognostically
significant oncosuppressor genes, p53 methylation is particu-
larly interesting. p53 inactivation by mutations has been
reported to have a significant role in MDS biology, while the
role of p53 methylation in MDS is not well defined. p53-
deficient mouse embryo fibroblasts, lacking functional p53
expression, were shown to have low sensitivity to the cytotoxic
Table 2 Associations between patients’ characteristics and TET2
mutations








Males (25) 7 18 0.7
Females (13) 5 8
FAB classification
RAEB (22) 6 16 0.08a
RAEB-t (12) 3 9
CMML (4) 3 1
IPSS
Int-2 (26) 8 18 1
High (12) 4 8
Blood counts
Hemoglobin (g/dl) 10 (8.3–12.2) 9 (5.9–12.2) 0.2
Platelets (109/l, median, range) 26.5 (11–77) 61.5 (10–573) 0.08
Neutrophil (109/l, median, range) 1.3 (0.2–6.1) 0.9 (0.1–5.3) 0.2
Previous LR-MDS
Yes (14) 3 11 0.7
No (21) 7 14
MDS duration before 5-AZA
Months (median, range) 8.1 (0.9–13.1) 7.3 (0.9–21.4) 0.83
Response
CR, PR, HI (10) 5 5 0.25
Stable, progressive (22) 6 16
Abbreviations: CMML, chronic myelomonocytic leukemia; CR, com-
plete remission; FAB, French-American-British classification;
HI, hematological improvement; LR-MDS, low-risk MDS; MDS,
myelodysplastic syndromes; PR, partial remission; RAEB, refractory
anemia with excess blasts.
aRAEB/RAEB-t versus CMML (CMML-1:1 patient; CMML2:3 patients).
Table 3 Description of 4 methylation patterns, identified by
principal component analysis, able to explain over 65% of sample
variance
Rotated factor pattern

















TP53 0.25 0.9 0.28
NRCAM 0.38 0.36
PTEN 0.27 0.85
Foxo3 0.28 0.22 0.8
PNPLA8 0.21 0.21 0.48
KLF5 0.24
Values in bold are those with the strongest association with the
principal component (PC).
Figure 2 Negative prognostic role of BCL2L10 hypermethylation.
The prognostic role of BCL2L10 methylation was confirmed in an
independent group of 27 higher-risk MDS patients, treated with 5-AZA
at standard doses. Patients with with over 50% BCL2L10 methylation
had a significantly lower probability of overall survival (P¼0.04).
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function of decitabine.12 In this line, efficacy of epigenetic
therapy may be influenced by p53 inactivation by methylation.
Among genes included in the third component, a higher
methylation rate of the apoptosis gene BCL2L10 was in
particular significantly associated to worse overall survival in
patients enrolled into the Gimema MDS0205 multicenter trial.
This was confirmed in an independent group of 27 higher-risk
MDS patients, treated with 5-AZA at standard doses (Table 1). In
both test and validation groups, there were no associations
between BCL2L10 methylation, studied as continuous variable,
and patient characteristics including age, sex, type and duration
of MDS, BM-blast count, WBC, hemoglobin levels, platelet
counts and IPSS. Patients with BCL2L10 methylation had a
lower probability of achieving response (including complete
remission, partial remission and hematological improvement,
P¼ 0.047). This translated into a significantly lower probability
of overall survival for patients with over 50% BCL2L10
methylation (P¼ 0.04, Figure 2). At a median follow-up of 10
months (range 0.6–40 months), all seven patients (three with
high and four with Int-2 IPSS) with BCL2L10 methylation below
50% were alive, indicating an independent prognostic role of
BCL2L10 methylation. These data show that BCL2L10 methyla-
tion may predict response to 5-AZA in MDS patients. BCL2L10
is a member of the BCL2 family with contradictory functions in
apoptosis. Most recently, a prevalent antiapoptotic function has
been described for BCL2L10 protein overexpression in gastric
cancer, through activation of the pro-survival activity of the
IKK–NF-kB pathway.13 It is likely that higher methylation levels
may be responsible for resistance to demethylation and impair
restoration of BCL2L10 expression following epigenetic treat-
ment. In this model, higher rates of BCL2L10 promoter
methylation would contrast the apoptotic effect of 5-azacytidine
treatment and negatively impact survival. Accordingly, reduced
BCL2L10 expression has been shown to function as independent
negative prognosticator of gastric carcinoma.13
In conclusion, TET2 mutations are a recurrent finding in
higher-risk MDS patients, but did not have an impact on the
methylation profile of a 22-gene array and on the response to
epigenetic treatment in our patients. Methylation profiling, in
particular for the BCL2L10 gene could identify higher-risk MDS
patients with worse outcome following epigenetic treatment.
Prospective studies on larger patient numbers are warranted to
confirm this finding.
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